EDAN Instruments Reveals Upgrades to Acclarix LX9 Ultrasound System
System and upgrades awaiting U.S. FDA clearance
DUBAI-China-based global healthcare company EDAN Instruments, Inc., unveiled its next-generation diagnostic ultrasound system Acclarix LX9 during Arab Health 2020.
The Acclarix LX9 system is currently awaiting 510(k) clearance from the U.S. Food and Drug Administration.
With Acclarix LX9, EDAN is adding artificial intelligence (AI) technologies to its existing ultrasound family. New features include eOB, eLV, eFollicle, eVolFlow, and eNT, all of which, according to Alice Bai, EDAN’s ultrasound clinical application manager, are designed to optimize workloads for sonographers in a various departments, such as obstetrics, gynecology, cardiology, and general surgery.
In addition to the additional AI features, LX9 also offers a 21.5-inch, high resolution LCD screen equipped with a new EIS+ platform that improves image quality. The integrated user interface can also be rotated 180 degrees.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
